Matt Gethers: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
| Line 29: | Line 29: | ||
</biblio> | </biblio> | ||
Treatments exist for preventive and palliative treatment of sickle cell episodes, but no treatment has yet been developed to mitigate the effects of an attack | Treatments exist for preventive and palliative treatment of sickle cell episodes, but no treatment has yet been developed to mitigate the effects of an attack once it has started. We feel we can develop a treatment for an ongoing attack by addressing the molecular basis of the pathology. | ||
Revision as of 08:08, 13 April 2008
I'm currently a sophomore in course 20. When I'm behaving myself, I'm allowed to work in the Endy Lab at MIT. I have links to my UROP projects and 20.109 work directly below.
UROP Projects
20.109 Work
20.310 Project
- Galkin O, Pan W, Filobelo L, Hirsch RE, Nagel RL, and Vekilov PG. Two-step mechanism of homogeneous nucleation of sickle cell hemoglobin polymers. Biophys J. 2007 Aug 1;93(3):902-13. DOI:10.1529/biophysj.106.103705 |
- Carragher B, Bluemke DA, Gabriel B, Potel MJ, and Josephs R. Structural analysis of polymers of sickle cell hemoglobin. I. Sickle hemoglobin fibers. J Mol Biol. 1988 Jan 20;199(2):315-31. DOI:10.1016/0022-2836(88)90316-6 |
- Bluemke DA, Carragher B, Potel MJ, and Josephs R. Structural analysis of polymers of sickle cell hemoglobin. II. Sickle hemoglobin macrofibers. J Mol Biol. 1988 Jan 20;199(2):333-48. DOI:10.1016/0022-2836(88)90317-8 |
- Carragher B, Bluemke DA, Becker M, McDade WA, Potel MJ, and Josephs R. Structural analysis of polymers of sickle cell hemoglobin. III. Fibers within fascicles. J Mol Biol. 1988 Jan 20;199(2):383-8. DOI:10.1016/0022-2836(88)90322-1 |
- Wang JC, Turner MS, Agarwal G, Kwong S, Josephs R, Ferrone FA, and Briehl RW. Micromechanics of isolated sickle cell hemoglobin fibers: bending moduli and persistence lengths. J Mol Biol. 2002 Jan 25;315(4):601-12. DOI:10.1006/jmbi.2001.5130 |
Treatments exist for preventive and palliative treatment of sickle cell episodes, but no treatment has yet been developed to mitigate the effects of an attack once it has started. We feel we can develop a treatment for an ongoing attack by addressing the molecular basis of the pathology.
